Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors
Status:
Recruiting
Trial end date:
2025-04-08
Target enrollment:
Participant gender:
Summary
This is a Phase 1, open label, multicenter, nonrandomized, multiple dose, safety,
tolerability, pharmacokinetic and pharmacodynamic study of PF-07220060 administered as a
single agent and then in combination with endocrine therapy.
In Part 1A, single escalating doses of PF-07220060 alone will be administered to determine
the maximum tolerated dose (MTD) and select the recommended phase 2 dose (RP2D).
In Part 1B and Part 1C, PF-07220060 will be administered in combination with 1 of 2 endocrine
therapies (letrozole and fulvestrant, respectively).
In Part 1D, food effect assessment of PF-07220060 at the RP2D dose level from the Part 1A
will be conducted.
Part 1B and Part 1C may commence at MTD or before reaching the MTD at a dose level in Part
1A.
Part 2B and Part 2C are expansion for combination therapy of PF-07220060 with letrozole and
fulvestrant, respectively.